作为首富李嘉诚医药版图的核心落子,和黄医药(00013.HK)日前同步披露的2025年年报与2026年一季度初步业绩报告,戳破了公司财务层面的纸面繁荣。2025年全年,公司归母净利润同比暴涨11倍,看似业绩迎来历史性突破,可超九成利润均来自出售资产的一次性收益,主营业务盈利几乎原地踏步。 进入2026年首季度,失去资产收益加持的业绩颓势显露,营收与利润双双大幅下滑,核心产品在国内市场持续跳水,...
Source Link作为首富李嘉诚医药版图的核心落子,和黄医药(00013.HK)日前同步披露的2025年年报与2026年一季度初步业绩报告,戳破了公司财务层面的纸面繁荣。2025年全年,公司归母净利润同比暴涨11倍,看似业绩迎来历史性突破,可超九成利润均来自出售资产的一次性收益,主营业务盈利几乎原地踏步。 进入2026年首季度,失去资产收益加持的业绩颓势显露,营收与利润双双大幅下滑,核心产品在国内市场持续跳水,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.